---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023058"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:56:30.753380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma FY 2023 net loss $69.0M; rezatapopt Phase 2 on track for Q1 2024

## Summary
- Cash, cash equivalents, and marketable securities $228.6M at Dec 31, 2023; cost savings from workforce reduction extend runway to end 2026.
- Rezatapopt Phase 1 data: confirmed ORR 38% at RP2D (2000 mg daily), median DOR 7 months in TP53 Y220C/KRAS WT patients.
- Registrational Phase 2 portion of PYNNACLE trial on track to initiate Q1 2024; FDA alignment on RP2D and key Phase 2 design elements.
- Phase 1 analysis in ovarian cancer subgroup selected as late-breaking oral presentation at 2024 SGO Annual Meeting on March 18.
- Net loss $69.0M vs $73.3M in 2022; R&D expenses $55.9M, G&A $24.2M.

## SEC filing metadata
- accession: 0000950170-24-023058
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/0000950170-24-023058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/pmvp-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023058
- JSON: https://secwatch.observer/filing/0000950170-24-023058.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023058.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3.
  - Period: the year ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017024023058/0000950170-24-023058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.